Axsome Therapeutics (AXSM) to Release Quarterly Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) is anticipated to announce its Q4 2024 earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.97) per share and revenue of $117.83 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. On average, analysts expect Axsome Therapeutics to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Axsome Therapeutics Stock Down 0.8 %

Shares of AXSM traded down $1.00 on Wednesday, hitting $127.09. 519,786 shares of the stock traded hands, compared to its average volume of 1,091,026. Axsome Therapeutics has a one year low of $64.11 and a one year high of $134.18. The company has a market capitalization of $6.16 billion, a PE ratio of -19.46 and a beta of 1.05. The business has a 50 day simple moving average of $98.47 and a 200 day simple moving average of $93.68. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have commented on AXSM. Leerink Partners lifted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Mizuho boosted their price objective on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the company an "outperform" rating in a report on Tuesday, February 11th. Finally, Robert W. Baird raised their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $154.80.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.